Cargando…

Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus

Aims. To evaluate carotid intima-media thickness (cIMT) and biomarkers of the osteoprotegerin/receptor activator of nuclear factor-κB ligand (OPG/RANKL) system in type 1 diabetes (T1DM) children and adolescents and controls. Subjects and Methods. Fifty six T1DM patients (mean ± SD age: 12.0 ± 2.7 ye...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lambrinoudaki, Irene, Tsouvalas, Emmanouil, Vakaki, Marina, Kaparos, George, Stamatelopoulos, Kimon, Augoulea, Areti, Pliatsika, Paraskevi, Alexandrou, Andreas, Creatsa, Maria, Karavanaki, Kyriaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833004/ https://www.ncbi.nlm.nih.gov/pubmed/24288529 http://dx.doi.org/10.1155/2013/102120

Ejemplares similares

Osteoprotegerin as a Marker of Atherosclerosis in Diabetic Patients
por: Augoulea, Areti, et al.
Publicado: (2013)

OR17-07 Retinol Binding Protein 4 Predicts Functional Vascular Disease in Early Postmenopausal Women
por: Armeni, Eleni, et al.
Publicado: (2020)

Dietary patterns are associated with arterial stiffness and carotid atherosclerosis in postmenopausal women
por: Karagkouni, Iliana, et al.
Publicado: (2022)

Association of menopausal symptoms with sociodemographic factors and personality traits
por: Augoulea, Areti, et al.
Publicado: (2020)

Osteoprotegerin Gene Polymorphisms Are Associated with Subclinical Atherosclerosis in the Mexican Mestizo Population
por: Cazarín-Santos, Benny Giovanni, et al.
Publicado: (2022)

Determinants of Secondary Hyperparathyroidism in Bariatric Patients after Roux-en-Y Gastric Bypass or Sleeve Gastrectomy: A Pilot Study
por: Alexandrou, Andreas, et al.
Publicado: (2015)

Psychosomatic and vasomotor symptom changes during transition to menopause
por: Augoulea, Areti, et al.
Publicado: (2019)

Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis
por: D'Abramo, Alessandra, et al.
Publicado: (2014)

Ovarian volume is associated with adiposity measures and bone mineral density in postmenopausal women
por: Armeni, Eleni, et al.
Publicado: (2018)

Previous Gestational Diabetes Mellitus and Markers of Cardiovascular Risk
por: Vrachnis, Nikolaos, et al.
Publicado: (2012)

Osteoprotegerin and MTHFR gene variations in rheumatoid arthritis: association with disease susceptibility and markers of subclinical atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2022)

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance
por: YU, XIUCHUN, et al.
Publicado: (2013)

Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease
por: Oğuz, Didem, et al.
Publicado: (2016)

The Role of Osteoprotegerin and Its Ligands in Vascular Function
por: Rochette, Luc, et al.
Publicado: (2019)

Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health
por: Tabari, Zahra Alizadeh, et al.
Publicado: (2013)

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
por: Burgess, Teresa L., et al.
Publicado: (1999)

Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin
por: Zauli, Giorgio, et al.
Publicado: (2008)

Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients
por: Carmona-Fernandes, Diana, et al.
Publicado: (2011)

Effect of Breastfeeding on Serum Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Kappa B Ligand in Full Term Neonates
por: Rafeey, Mandana, et al.
Publicado: (2013)

Production of Soluble Receptor Activator of Nuclear Factor Kappa-Β Ligand and Osteoprotegerin by Apical Periodontitis Cells in Culture and Their Modulation by Cytokines
por: Duka, Miloš, et al.
Publicado: (2019)

Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
por: Park, Hye-Rim, et al.
Publicado: (2003)

Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2016)

Association of thyroid function with arterial pressure in normotensive and hypertensive euthyroid individuals: A cross-sectional study
por: Saltiki, Katerina, et al.
Publicado: (2008)

Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin
por: D'Abramo, Alessandra, et al.
Publicado: (2013)

Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function
por: Collado, Sílvia, et al.
Publicado: (2017)

Subclinical atherosclerosis in patients with psoriasis
por: Balta, Ilknur, et al.
Publicado: (2015)

Diabetes and Subclinical Coronary Atherosclerosis
por: Lee, Chang Hoon, et al.
Publicado: (2018)

Predictors of subclinical atherosclerosis in HIV
por: Fernández Soto, Julia, et al.
Publicado: (2023)

Effects of High and Low Doses of Folic Acid on the Soluble Receptor Activator of Nuclear Factor-kappa B Ligand/Osteoprotegerin Ratio during Pregnancy
por: FATHI MAROUFI, Nazila, et al.
Publicado: (2017)

Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients
por: Pateinakis, Panagiotis, et al.
Publicado: (2013)

The Proinflammatory Soluble CD40 Ligand Is Associated with the Systemic Extent of Stable Atherosclerosis
por: Pereira-da-Silva, Tiago, et al.
Publicado: (2021)

Noninvasive indicators of atherosclerosis in subclinical hypothyroidism
por: Kilic, Ismail Dogu, et al.
Publicado: (2013)

Association of Fat Density With Subclinical Atherosclerosis
por: Alvey, Nicholas J., et al.
Publicado: (2014)

Subclinical atherosclerosis: how and when to treat it?
por: Gatto, Laura, et al.
Publicado: (2020)

Biomarkers of subclinical atherosclerosis in patients with psoriasis
por: Kaiser, Hannah, et al.
Publicado: (2021)

Serum osteoprotegerin level in hemodialysis patients using low‐flux reused dialyzer in relation to atherosclerosis
por: Do Van, Tung, et al.
Publicado: (2021)

Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis
por: Giaginis, Constantinos, et al.
Publicado: (2012)

Therapeutic implications of osteoprotegerin
por: Fili, Sofia, et al.
Publicado: (2009)

The role of osteoprotegerin in arthritis
por: Schett, Georg, et al.
Publicado: (2003)

Osteoprotegerin in Cardiometabolic Disorders
por: Pérez de Ciriza, C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_59meumh1mkr2ern0dk2ieg3826